Autoimmunity

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
Thursday, March 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

Global Down Syndrome Foundation Applauds House Energy & Commerce Committee for Advancing Legislation to Authorize Down Syndrome Research Program at NIH

Retrieved on: 
Tuesday, March 12, 2024
African Americans, Congress, Down syndrome, Autoimmunity, Investigation, Memory, INCLUDE, Ranking, Patient, Inflammation, Research, Human services, Syndrome, NIH, CO, Legislation, Member of Congress, Bangladesh Technical Education Board, Representative, Hearing, Pharmaceutical industry

7406), which would authorize the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project at the National Institutes of Health (NIH).

Key Points: 
  • 7406), which would authorize the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project at the National Institutes of Health (NIH).
  • The legislation will formally authorize a trans-NIH structure to ensure that major crosscutting issues and opportunities within Down syndrome research are identified and allow for multiple institutes to collaborate on a research plan.
  • This will enable institute coordination to plan, fund, and share and disseminate research results that aim to improve health outcomes for those with Down syndrome.
  • To read about the impactful research that the INCLUDE Project has funded visit the NIH Down Syndrome Coordinating Center Website at: https://includedcc.org/.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Retrieved on: 
Tuesday, March 12, 2024
Development, Gene editing, AID, Patient, SAN, Research, Cancer, Research and development, Imagination, Therapy, CRISPR, Kite Pharma, Autoimmunity, Autoimmune disease, Pharmaceutical industry

“The potential for CAR T as a therapeutic option for autoimmune disease has captured the collective imagination of the scientific community,” said Zachary Roberts, M.D., Ph.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene.

Key Points: 
  • “The potential for CAR T as a therapeutic option for autoimmune disease has captured the collective imagination of the scientific community,” said Zachary Roberts, M.D., Ph.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene.
  • “Accordingly, this excitement created a new field for CAR T that has become quickly crowded, making differentiation key for future success.
  • Allogene’s first AID AlloCAR T investigational product is expected to enter Phase 1 clinical trials in early 2025.
  • “We look forward to our collaboration with Allogene as they leverage our extensive gene-editing technologies to develop novel, differentiated allogeneic CAR T therapeutics for autoimmune diseases.”

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024

Retrieved on: 
Monday, April 1, 2024
Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, IgA nephropathy, Congress, Immunoglobulin A, Inflammation, Nephrology, Exhibition, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina.
  • Concurrently with the poster presentation, the Company will host an investor event on Monday, April 15th.
  • Poster Title: Updated Results from the RUBY-3 study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist in IgA Nephropathy
    Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium
    Location: Exhibition Hall and Main Foyer, Buenos Aires Convention Center, Buenos Aires, Argentina

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Research, Biotechnology, Other Health, Health, Cosmetics, Pharmaceutical, Retail, Science, Oncology, Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points: 
  • Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, IgA nephropathy, Brain, Isoelectric point, WT, Lupus, Patient, Lung, Tissue, Immunoglobulin A, SLE, Doctor of Philosophy, Inflammation, MD, Skin, Alpine, Kidney, Technical, Atomic mass, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.
  • BAFF- and APRIL-related genes are increased in myeloid and B cells in systemic lupus erythematosus (SLE) patients compared to healthy adults.
  • Povetacicept significantly reduces multiple disease parameters in the NZB/W mouse model of lupus, more effectively than WT TACI-Ig or B cell depletion.
  • These findings are particularly intriguing considering that these organs are of particular relevance to our lead indications, systemic lupus erythematosus and IgA nephropathy.

Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Doctor of Philosophy, Conference, Autoimmunity, Inflammation, ALPN

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.
  • Thursday, March 28th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company will host investor meetings the same day.
  • Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.